MetaCap

BioNexus Gene Lab (BGLC) vs Sera Prognostics (SERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sera Prognostics is the larger company by market cap ($72.0 million vs $2.0 million), about 36.1 times the size. BioNexus Gene Lab converts more of its revenue into profit, with a net margin of -40.2% versus -39417.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BGLC-49.25%SERA-12.56%
+9%-22%-52%
Oct 7, 20261 yearNov 20, 2026
BGLC-47.29%SERA-11.27%
+10%-20%-50%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BGLC versus SERA key metrics
MetricBGLCSERA
Share price$0.68$1.81
Market cap$1.99M$71.98M
1-day change0.00%-4.23%
YTD return—-38.64%
1-year return—-43.96%
5-year return—-83.55%
EPS (TTM)$-1.26$-0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.42M$81.00K
Revenue growth (YoY)-21.93%+5.19%
Net income (latest FY)$-2.98M$-31.93M
Gross margin14.62%-102.47%
Operating margin-39.93%-45066.67%
Net margin-40.20%-39417.28%
52-week high$4.97$3.85
52-week low$0.621$1.56
Distance from 52-week high-86.32%-52.99%
Analyst consensus—none
Avg. price target upside—+203.87%
Average volume6.70K27.84K
Shares outstanding2.93M38.80M
Employees1971
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Sera Prognostics is about 36.1 times larger than BioNexus Gene Lab by market value ($71.98M vs $1.99M).
  • BioNexus Gene Lab is more profitable, keeping -40.2 cents of every revenue dollar as net income versus -39417.3 cents for Sera Prognostics.
  • Sera Prognostics grew revenue faster in its latest fiscal year (+5.19% vs -21.93%).

About BioNexus Gene Lab

BGLC stock →

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.

Health Care · Medical Specialities · 19 employees

About Sera Prognostics

SERA stock →

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.

Health Care · Medical Specialities · 71 employees

BGLC vs SERA FAQ

Which is bigger, BioNexus Gene Lab or Sera Prognostics?

Sera Prognostics (SERA) is larger, with a market capitalization of $71.98M compared with $1.99M for BioNexus Gene Lab (BGLC).

Are BioNexus Gene Lab and Sera Prognostics in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons